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Abstract
Sympathetic nervous system hyperactivity has a well-recognized role in the pathophysiology of heart failure with reduced left
ventricular ejection fraction. Alterations in sympathetic nervous system have been related to the pathophysiology of pulmonary
arterial hypertension, but it is unclear whether cardiac sympathetic nervous system is impaired and how sympathetic dysfunction
correlates with hemodynamics and clinical status in pulmonary arterial hypertension patients. The aim of this study was to evaluate
the cardiac sympathetic nervous system activity by means of 123Iodine-metaiodobenzylguanidine nuclear imaging in pulmonary
arterial hypertension patients and to explore its possible correlation with markers of disease severity. Twelve consecutive pulmon-
ary arterial hypertension patients (nine women, median age 56.5 (17.8), eight idiopathic and four connective tissue-associated
pulmonary arterial hypertension) underwent cardiac 123Iodine-metaiodobenzylguanidine scintigraphy. The results were compared
with those of 12 subjects with a negative history of cardiovascular or pulmonary disease who underwent the same nuclear imaging
test because of a suspected paraganglioma or pheochromocytoma, with a negative result (controls), and 12 patients with heart failure
with reduced left ventricular ejection fraction. Hemodynamics, echocardiography, six-minute walking distance, cardiopulmonary
exercise testing, and N-terminal pro brain natriuretic peptide were collected in pulmonary arterial hypertension patients within one
week from 123Iodine-metaiodobenzylguanidine scintigraphy. Cardiac 123Iodine-metaiodobenzylguanidine uptake, assessed as early
and late heart-to-mediastinum ratio, was significantly lower in pulmonary arterial hypertension compared to controls (p¼ 0.001),
but similar to heart failure with reduced left ventricular ejection fraction. Myocardial 123Iodine-metaiodobenzylguanidine turnover,
expressed as washout rate, was similar in pulmonary arterial hypertension and heart failure with reduced left ventricular ejection
fraction and significantly higher compared to controls (p¼ 0.016). In the pulmonary arterial hypertension group, both early and late
heart-to-mediastinum ratios and washout rate correlated with parameters of pulmonary arterial hypertension severity including
pulmonary vascular resistance, right atrial pressure, tricuspid annular plane systolic excursion, N-terminal pro brain natriuretic
peptide, and peak VO2. Although we evaluated a small number of subjects, our study showed a significant impairment in cardiac
sympathetic nervous system in pulmonary arterial hypertension, similarly to that observed in heart failure with reduced left
ventricular ejection fraction. This impairment correlated with indices of pulmonary arterial hypertension severity. Cardiac sympa-
thetic dysfunction may be a contributing factor to the development of right-sided heart failure in pulmonary arterial hypertension.
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Introduction
Pulmonary hypertension (PH) is a pathophysiological dis-
order that characterizes several distinctive clinical
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conditions and can complicate the majority of cardiovascu-
lar and respiratory diseases.1 PH is deﬁned by the presence
of a mean pulmonary arterial pressure equal or higher than
25mmHg at rest as measured by right heart catheterization
and is categorized in ﬁve groups based on similar eti-
ology, clinical features, pathological ﬁndings, hemodynamic
characteristics, and treatment strategy.1 Group 1 refers
to pulmonary arterial hypertension (PAH), a rare clinical
condition that primarily aﬀects the pulmonary vascula-
ture leading to a chronic increase in right ventricular after-
load.1 Prognosis related to PAH is typically poor, and
mortality is mainly related to the development of right
heart failure.2
Recent advances in diagnosis, clinical management, and
pharmacological treatment have improved the prognosis of
PAH.3 Nevertheless, the disease is still associated with
marked morbidity and mortality, mainly related to the pro-
gressive development of right-sided heart failure that can
progress despite reduction in pulmonary afterload with spe-
ciﬁc pulmonary vasodilator treatment.4 A better under-
standing of the pathophysiological mechanisms that lead
to right ventricular dysfunction represents an urgent
unmet need. An alteration in neurohormonal signaling
may act as candidate pathogenic contributor to the progres-
sive pulmonary vascular remodeling process and the devel-
opment of right heart failure.5 The detrimental role of
chronic sympathetic hyperactivation, and its implications
on both disease progression and mortality, has been
widely recognized in the ﬁeld of left-sided heart failure
and represents the rationale for adrenergic receptor blocker
therapy.6
Nuclear imaging has a well-established role in the evalu-
ation of sympathetic nervous activity in several clinical set-
tings. In particular, cardiac nuclear imaging with 123Iodine-
metaiodobenzylguanidine (123I-MIBG) allows measurable
assessment of sympathetic dysfunction of the left ventricle
(LV) secondary to chronic systemic adrenergic hyperactiva-
tion, typically present in patients with heart failure with
reduced LV ejection fraction (HFrEF).7 Importantly, car-
diac sympathetic dysfunction has prognostic signiﬁcance in
development of arrhythmia and sudden cardiac death in
these patients.8–10
Some studies suggested an increased systemic sympa-
thetic activity in patients with PAH,11,12 highlighting an
impairment of cardiac autonomic innervation by cardiac
123I-MIBG study13–15; however, the impact of such alter-
ations on clinical status and their correlation with hemo-
dynamics and functional parameters have not been
completely elucidated.
In the present study, we sought to (1) explore the pres-
ence and type of cardiac sympathetic dysfunction in patients
with PAH in comparison to healthy subjects and patients
with HFrEF; and (2) evaluate possible correlations with
hemodynamic, clinical, and functional parameters.
Some of the results of this study have been previously
reported in abstract form.16
Methods
Patients
Patients referred to the Pulmonary Hypertension Outpatient
Clinic of the Federico II University of Naples for right heart
catheterization (for diagnostic or follow-up evaluation) were
prospectively enrolled between February 2015 and June
2016. Inclusion criteria were age 18 years and group 1
PAH diagnosis according to current guidelines’ criteria
(mean pulmonary artery pressure 25mmHg at rest mea-
sured at right heart catheterization, along with a pulmonary
capillary wedge pressure 15mmHg and a pulmonary vas-
cular resistance greater than 3Wood units).1 All patients
with other causes of PH (i.e. due to heart disease, severe
lung disease, chronic thromboembolic PH, etc.) were
excluded. Furthermore, we excluded patients who presented
any condition that could potentially interfere with the
results of MIBG imaging (i.e. treatment with any medica-
tion interfering with norepinephrine neuronal uptake, diag-
nosis of diabetes mellitus, autonomic neurological disorders
such as Shy Drager syndrome, pheochromocytoma, or any
contraindication to nuclear imaging, such as pregnancy).
The results of 123I-MIBG imaging in PAH patients were
compared with healthy subjects (control group) who under-
went 123I-MIBG scintigraphy to rule out a paraganglioma
or a pheochromocytoma; these patients were selected among
those showing low clinical probability, and all had negative
radionuclide imaging for paraganglioma or a pheochromo-
cytoma and no evidence of neurological or cardiac diseases.
The results of 123I-MIBG imaging in the study popula-
tion were also compared with a group of patients with
HFrEF (idiopathic dilated cardiomyopathy or due to ische-
mic heart disease), in NYHA class II or III, who underwent
123I-MIBG because of enrollment in other research
protocols.17
The study was performed in accordance with the
Declaration of Helsinki on human research and the Good
Clinical Practice standards. The local Ethical Committee
approved the study protocol and all the patients included
in the study gave their written informed consent after receiv-
ing an accurate explanation of the study protocol and of the
potential risks related to the procedures provided by the
study protocol.
Procedures
At the time of enrollment, all PAH patients underwent com-
plete clinical examination and assessment of serum N-term-
inal pro brain natriuretic peptide (NT-proBNP).
Demographic data, medical history, and concomitant medi-
cations were also collected. The following procedures were
performed within a one-week period.
Transthoracic echocardiography. Standard transthoracic echo-
cardiography was performed at the Internal Medicine
Echocardiography Laboratory using a Philips iE33 machine
2 | Cardiac sympathetic dysfunction in pulmonary arterial hypertension Mercurio et al.
with subjects in the left lateral decubitus position.
Measurements were performed oﬀ-line by an experienced
echocardiographer (VM) according to current guidelines
for the left and right chambers evaluation.18
Six-minute walking distance. Six-minute walking test was per-
formed according to the American Thoracic Society guide-
lines,19 and the Borg scale dyspnea index was collected at the
end of the test.
Cardiopulmonary exercise testing (CPET). Incremental symptom-
limited CPET was performed using a bicycle ergometer
according to the current guidelines under continuous
12-lead electrocardiographic monitoring and every 2min
noninvasive blood pressure measurement.19 After a 3min
warm-up period at unloaded cycling, a ramp protocol at a
workload established by the sex-, age-, height-, and weight-
adjusted Wassermann formula [(predicted peak VO2  pre-
dicted rest VO2)/100] was started.
Respiratory gas exchange measurements were obtained
breath-by-breath by means of a computerized metabolic
cart (Ultima CardiO2, MedGraphics Cardiorespiratory
Diagnostics). Peak VO2 was recorded as the mean value of
VO2 during the last 20 s of the test and expressed in milli-
liters per kilogram per minute. The ventilatory anaerobic
threshold was noninvasively detected by two experienced
reviewers (GC and PP) using a ‘‘dual method approach’’
with the V-slope method and the ventilatory equivalent for
O2 method.
Right heart catheterization. With patients resting in a supine
position, a Swan-Ganz catheter was advanced through
venous femoral access under ﬂuoroscopic guidance to meas-
ure right atrial pressure, pulmonary arterial pressure, and
pulmonary arterial wedge pressure at end-expiration.
Cardiac output was measured by thermodilution using an
average of three measurements. Pulmonary vascular resist-
ance was calculated using the formula: [(mean pulmonary
arterial pressure  pulmonary wedge pressure)/ cardiac
output] and expressed in Wood Units.
Cardiac 123I-MIBG imaging. All enrolled patients underwent
cardiac 123I-MIBG according to the recommendations of
the European Association of Nuclear Medicine
Cardiovascular Committee and the European Council of
Nuclear Cardiology,20,21 as previously described.17
An activity of 111 MBq 123I-MIBG (Covidien,
Mallinckrodt) was intravenously administered over
1–2min after thyroid blockade by oral administration of
Lugol’s solution. Ten-minute planar images of the thorax
in standard anterior view (256 256 matrix) were performed
15min (early image) and 3 h and 50min (late image) after
tracer administration. Four hours after tracer administra-
tion, a SPECT study was performed; it was obtained in
step and shoot mode, with 90 projections, an imaging time
30min and stored in a 64 64 matrix.Planar and
tomographic imaging was performed using a dual-head
camera system (Skylight, Philips) equipped with a low-
energy, parallel-hole, high-resolution collimator, and the
camera peaked at 159 keV with a symmetrical 20% energy
window. On the planar MIBG images, using dedicated post-
processing software on a dedicated workstation (Philips), a
cardiac region of interest (ROI), polygonal in shape, was
manually drawn over the epicardial border including the
left ventricular cavity. Care was taken to exclude lung and
liver from the myocardial ROI. The mediastinal ROI with a
square shape was placed on the upper half of the mediasti-
num and had a size of 7 7 pixels. The location of the
mediastinal ROI was determined using as landmarks the
lung apex, the upper cardiac border, and the medial con-
tours of the lungs. From early and late planar images, the
heart-to-mediastinum (H/M) ratio was computed by divid-
ing the mean counts per pixel within the myocardium by the
mean counts per pixel within the mediastinum. The MIBG
washout rate (WR), decay and background corrected, was
calculated using the following formula: ([early heart counts
per pixel  early mediastinum counts per pixel]  [late heart
counts per pixel decay-corrected  late mediastinum counts
per pixel decay corrected])/(early heart counts per pixel 
early mediastinum counts per pixel)100. SPECT studies
were processed with ﬁltered back-projection and recon-
structed into standard long-axis and short-axis images, per-
pendicular to the heart axis. The interpretation of images
was done by consensus of two independent expert readers,
with previously demonstrated excellent intra- and inter-
observer reproducibility.17 No patient was excluded for
poor quality of 123I-MIBG images.
Statistical analysis
Continuous variables are expressed as median (interquartile
rage) and were compared using ANOVA test and Mann–
Whitney test followed by Bonferroni correction. Discrete
variables are expressed as absolute numbers or percentage
and compared using chi square test. Pearson correlation
analysis was performed to evaluate the correlations between
cardiac 123I-MIBG parameters and hemodynamics, instru-
mental, and serum data in PAH patients. All data were col-
lected and entered in an Excel database, and statistical
analysis was performed using SPSS (IBM SPSS Statistics
19 Version). A p value< 0.05 was considered as statistically
signiﬁcant.
Results
Patient characteristics
Among the patients that were consecutively referred to our
Pulmonary Hypertension Outpatient Clinic for right heart
catheterization between February 2015 and June 2016, 12
PAH patients, 9 women and 3 men, median age of 56.5
(17.8) years gave their consent to participate in the study.
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Eight patients had idiopathic PAH and four had PAH asso-
ciated with connective tissue disease (in two cases systemic
sclerosis, one undiﬀerentiated connective tissue disease, and
one systemic erythematosus lupus). Five were incident cases
who were referred for a diagnostic right heart catheteriza-
tion, and seven were prevalent cases who needed a follow-up
right heart catheterization. Control group included 12 sub-
jects, 8 women and 4 men, with a median age of 54.5 (10)
years. The group of HFrEF patients included 12 patients, 9
women and 3 men with a median age of 60 (9.5) years, in
NYHA class II or III (6 in II and 6 in III) with a moderate
reduction of left ventricular ejection fraction, with a median
value of 34.5 (7.75)%. Eighty-three percent of them had
ischemic etiology, and 17% were diagnosed with idiopathic
dilated cardiomyopathy. The three groups were comparable
in terms of age, sex, and anthropometrics characteristics
(Table 1).
Clinical, hemodynamic, echocardiographic, and serologic
data of the PAH patients are summarized in Table 2.
Prevalent patients were receiving treatment with pulmonary
vasodilator drugs, the majority of them as combination
therapy with a phosphodiesterase-5 inhibitor (tadalaﬁl)
and an endothelin receptor antagonist (ambrisentan or
bosentan). Hemodynamics revealed a high right atrial pres-
sure, a severe increase in mean pulmonary arterial pressure,
with a normal pulmonary capillary wedge pressure, and a
low cardiac output. Pulmonary vascular resistance was
severely increased. Echocardiographic evaluation of the
right chambers revealed a dilated right atrium, a severe
increase in estimated systolic pulmonary arterial pressure,
and a borderline right ventricular systolic function (tricuspid
annular plane systolic excursion (TAPSE) within the lower
limits of normal and a reduced right ventricular S0 wave).
Six-minute walking distance was 380 (166.3)m and Borg
dyspnea index 3.5 (3.3). At CPET, PAH patients had a
low VO2 peak and VO2 pulse, with an increase in VE/
VCO2 slope and a reduced end-tidal pCO2.
Cardiac 123I-MIBG imaging
The results of 123I-MIBG imaging are summarized in
Table 3. The analysis of MIBG imaging parameters high-
lighted a signiﬁcant diﬀerence in H/M ratios and WR
among the groups. In particular, early H/M was signiﬁ-
cantly reduced in PAH patients in comparison to the control
group (1.95 (0.50) versus 2.20 (0.20), p¼ 0.0259), and there
was no signiﬁcant diﬀerence when compared with HFrEF
patients (1.92 (0.24), p¼ns) (Fig. 1). Also, late H/M in PAH
Table 1. Characteristics of enrolled subjects.
PAH
(n¼ 12)
HFrEF
(n¼ 12)
Controls
(n¼ 12)
Sex M/F (n) 3/9 3/9 4/8
Age (years) 56.5 (17.8) 60 (9.5) 54.5 (10)
BMI (kg/m2) 27.3 (7.3) 26 (10.5) 24 (7)
HR (bpm) 73.5 (17) 66.5 (20.8) 68 (12)
SBP (mmHg) 110 (17.5) 107.5 (36.3) 115 (20)
DBP (mmHg) 70 (20) 67.5 (18.8) 70 (10)
BMI: body mass index; DBP: diastolic blood pressure; HFrEF: heart failure with
reduced left ventricular ejection fraction; HR: heart rate; PAH: pulmonary arter-
ial hypertension; SBP: systolic blood pressure.
Data are expressed as median (interquartile range) or as absolute number.
Group comparisons were performed using Mann–Whitney nonparametrical
analysis for continuous variables and 2 statistics for categorical variables, as
appropriate. A p< 0.05 was considered as statistically significant. No significant
differences among groups were observed (p¼ ns).
Table 2. Clinical, hemodynamic, instrumental, and serum data of
PAH patients.
PAH patients
(n¼ 12)
WHO functional class
I/II/III/IV (n) 0/6/6/0
Pulmonary vasodilator treatment (n¼ 7)
Phosphodiesterase-5 inhibitor 5
Endothelin receptor antagonist 6
Prostacyclin analogue 1
Combination therapy 5
Right heart catheterization
Right atrial pressure (mmHg) 9.5 (3.3)
Mean pulmonary arterial pressure (mmHg) 48 (11.3)
Systolic pulmonary arterial pressure (mmHg) 65 (18.8)
Diastolic pulmonary arterial pressure (mmHg) 34 (10)
Cardiac output (l/min) 3.8 (2.2)
Cardiac index (l/min/m2) 2.1 (1.3)
Pulmonary vascular resistance (Wood Units) 9.5 (4.8)
Pulmonary capillary wedge pressure (mmHg) 9.5 (2)
Transthoracic echocardiography
Right atrial area (cm2) 20.5 (5)
Estimated systolic pulmonary arterial
pressure (mmHg)
77.5 (36.3)
TAPSE (mm) 17 (3)
Right ventricular S0 wave (cm/s) 10 (2.6)
Six-minute walking distance (n¼ 10)
Distance walked (m) 380 (166.3)
Borg scale dyspnea 3.5 (3.3)
Cardiopulmonary exercise testing (n¼ 10)
VO2 peak (ml/min/kg) 13.7 (4.2)
VE/VCO2 slope 36.0 (8.5)
VO2 pulse (ml/min/kg/bpm) 7.5 (3.3)
End-tidal pCO2 (mmHg) 29 (6)
Serum biomarker
NT-proBNP (pg/dl) 279.5 (153.5)
NT-proBNP: N-terminal pro brain natriuretic peptide; PAH: pulmonary arterial
hypertension; pCO2: carbon dioxide partial pressure; TAPSE: tricuspid annular
plane systolic excursion; VCO2: carbon dioxide production; VE: minute venti-
lation; VO2: oxygen consumption per kg/min; WHO: World Health
Organization.
Data are expressed as median (interquartile range) or as absolute number.
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patients was signiﬁcantly reduced in comparison to controls
(1.65 (0.49) versus 2.10 (0.28), p¼ 0.001), and there was
no signiﬁcant diﬀerence with HFrEF patients (1.74 (0.29),
p¼ ns) (Fig. 1). Furthermore, WR was signiﬁcantly
increased in PAH patients in comparison to controls (27.5
(30.8)% versus 18.5 (3.8)%, p¼ 0.0156) and similar to
HFrEF patients (32.2 (11.2)%, p¼ns) (Fig. 1).
There was no statistically signiﬁcant diﬀerences in
123I-MIBG parameters among incident and prevalent PAH
patients or among diﬀerent PAH etiologies.
Correlation analysis in PAH patients
In Table 4 the results of the correlation analysis between
123I-MIBG and parameters deriving from hemodynamics,
echocardiography, CPET, six-minute walking distance,
and serologic data are summarized.
Although there was no signiﬁcant correlation with early
H/M, late H/M showed a signiﬁcant positive correlation
with cardiac index, TAPSE, and right ventricular S0 wave,
and an inverse correlation with pulmonary vascular resist-
ance and with NT-proBNP (Fig. 2). Furthermore, WR was
positively correlated with right atrial pressure and pulmon-
ary vascular resistance, with NT-proBNP, and VE/VCO2
slope. There was a negative correlation with TAPSE and
right ventricular S0 wave, with O2 pulse, VO2 peak, and
with distance walked (Fig. 3).
Discussion
In this study we demonstrate the presence of signiﬁcant
impairment in cardiac sympathetic activation in a small
but well-characterized cohort of patients with PAH using
123I-MIBG imaging. Furthermore, we found that this alter-
ation is correlated with several parameters of disease
severity.
Few prior studies, mainly performed on patients
with heterogeneous etiologies of PH, demonstrated cardiac
sympathetic dysfunction at 123I-MIBG imaging.13–15
Moreover, as additional new ﬁnding, we compared the char-
acteristics of cardiac sympathetic dysfunction in PAH
patients with data derived from patients with HFrEF, and
we showed that the alterations were similar between groups.
Sympathetic hyperactivity is a well-known hallmark of
HFrEF. It represents a compensatory mechanism aimed at
enhancing heart rate and contractility, and at raising sys-
temic blood pressure by means of peripheral vasoconstric-
tion. However, catecholamine overstimulation over time
leads to a reduction in myocardial beta 1-adrenergic recep-
tor expression and signaling.6 This deregulation is impli-
cated in the development of progressive cardiac adverse
remodeling and represents the rationale for the use of
beta-blockers for the treatment of HFrEF.6 Nuclear ima-
ging with 123I-MIBG can quantify the dysfunction of sym-
pathetic drive. In particular, a decrease in H/M ratio
indicates a downregulation of adrenergic receptors (norepin-
ephrine transporter 1) due to chronic increase in sympa-
thetic input, and an increase in WR is consequent to the
increased turnover of postsynaptic noradrenalin.8
Table 3. Cardiac 123I-MIBG findings in the enrolled patients.
123I-MIBG
PAH
(n¼ 12)
HFrEF
(n¼ 12)
Controls
(n¼ 12)
ANOVA
p value
Early H/M 1.95 (0.50)* 1.92 (0.24)** 2.20 (0.20) 0.008
Late H/M 1.65 (0.49) 1.74 (0.29)*** 2.10 (0.28) <0.0001
WR (%) 27.5 (30.8) 32.2 (11.2)** 18.5 (3.8) 0.019
ANOVA: analysis of variance; HFrEF: heart failure with reduced left ventricular
ejection fraction; H/M: heart-to-mediastinum ratio; 123I-MIBG: 123Iodine-metaio-
dobenzylguanidine; PAH: pulmonary arterial hypertension; WR: washout rate.
Data are expressed as median (interquartile range) Group comparisons were
performed using ANOVA test and Mann–Whitney analysis for continuous vari-
ables, and 2 statistics for categorical variables, as appropriate. A p< 0.05 was
considered as statistically significant.
*p< 0.05 versus controls; **p< 0.005 versus controls; ***p< 0.0005 versus
controls.
Fig. 1. Box plots of cardiac 123I-MIBG early H/M, late H/M, and WR in
PAH patients, HFrEF patients, and control subjects. HFrEF: heart failure
with reduced left ventricular ejection fraction; H/M: heart-to-medias-
tinum; PAH: pulmonary arterial hypertension; WR: washout rate.
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These alterations correspond to a decrease in myocardial
norepinephrine content and an increase in its spillover.8
Our results conﬁrm recent advances in the understanding
of the possible role of sympathetic hyperactivity in the
pathophysiology of PAH. Preclinical models of pulmonary
vascular pressure overload highlighted a correlation
between maladaptive right ventricular remodeling and dys-
function in cardiac sympathetic activity, evaluated both
in vivo and noninvasively with 123I-MIBG cardiac ima-
ging.22 It has been demonstrated that the increase in sym-
pathetic activity could be partially caused by increased
chemo-sensitivity and increased right ventricular ﬁlling
pressures.23
To date, whether circulating catecholamines are increased
or normal in PAH remains controversial.24 Nonetheless,
muscle sympathetic nerve activity was found to be markedly
increased in PAH,23 and a reduction in heart rate variability,
another marker of sympathetic hyperactivity, has been
demonstrated in both experimental and clinical studies.25
Furthermore, prolonged activation of the sympathetic ner-
vous system (SNS), as measured by microneurographic rec-
ording, was associated with a poor prognosis in PAH.11
The main advantage of 123I-MIBG imaging is related to
its organ-speciﬁcity in detecting cardiac alterations second-
ary to sympathetic system activation. Indeed, it is well
known that the rate of spillover of noradrenaline to
plasma is regional and organ-speciﬁc, with certain organs
experiencing the greatest degree of sympathetic activation.26
Furthermore, it has been demonstrated that increased car-
diac adrenergic drive precedes generalized sympathetic
Table 4. Correlations between cardiac 123I-MIBG parameters (late
H/M and WR) and hemodynamic, instrumental, and serum data in PAH
patients.
Late H/M WR
Parameter Pearson p Pearson p value
Right atrial pressure 0.5022 ns 0.7216 0.0081
Mean PAP 0.1945 ns 0.3242 ns
Cardiac index 0.7290 0.0072 0.3295 ns
Pulmonary vascular resistance 0.7373 0.0062 0.7490 0.0051
TAPSE 0.6830 0.0144 0.6517 0.0217
Right ventricular S0 wave 0.8604 0.0003 0.6424 0.0243
Right atrial area 0.2440 ns 0.5392 ns
Estimated SPAP 0.2212 ns 0.1974 ns
Six-minute walking distance 0.3894 ns 0.7683 0.0094
VO2 peak 0.2732 ns 0.7374 0.0149
VE/VCO2 slope 0.5914 ns 0.6447 0.0442
VO2 pulse 0.1807 ns 0.7047 0.0229
End-tidal pCO2 0.1992 ns 0.4419 ns
NT-proBNP 0.6239 0.0302 0.6926 0.0125
H/M: heart-to-mediastinum; 123I-MIBG: 123Iodine-metaiodobenzylguanidine;
NT-proBNP: N-terminal pro brain natriuretic peptide; PAH: pulmonary arterial
hypertension; PAP: pulmonary arterial pressure; pCO2: carbon dioxide partial
pressure; SPAP: systolic pulmonary arterial pressure; TAPSE: tricuspid annular
plane systolic excursion; VCO2: carbon dioxide production per minute; VE:
minute ventilation; VO2: oxygen consumption per kg/min; WR: washout rate.
A p< 0.05 was considered as statistically significant.
Fig. 2. Correlation between late H/M and hemodynamic, instrumental, and serum data in PAH patients. H/M: heart-to-mediastinum;
NT-proBNP: N-terminal pro brain natriuretic peptide; PVR: pulmonary vascular resistance; TAPSE: tricuspid annular plane systolic
excursion.
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activation in human heart failure.27 Therefore, the ability to
investigate the state of cardiac-speciﬁc sympathetic activity
makes 123I-MIBG imaging a better technique for character-
ization of the role of cardiac-speciﬁc SNS in the pathophysi-
ology of PAH, since its impairment may also precede
sympathetic dysfunction in other organs. Moreover,
123I-MIBG imaging has a validated role in the management
of HF patients, particularly for the assessment of HF sever-
ity and prognosis of HF patients. Several studies have
demonstrated the independent and incremental prognostic
role of cardiac 123I-MIBG imaging in HFrEF, thus helping
in risk-stratiﬁcation, in selection of therapeutic strategies,
and in predicting long-term survival.28
In our analysis, cardiac sympathetic dysfunction in PAH
patients correlated with echocardiographic measurements of
right ventricular function and with hemodynamic measures
(pulmonary vascular resistance and right atrial pressure)
that are well known prognostic markers, thus supporting
the notion that sympathetic activation is associated with
worse prognosis. However, it remains unclear whether this
is a cause or a consequence of right heart failure.11
Moreover, we demonstrated a signiﬁcant correlation
between WR% and CPET-derived parameters of exercise
capacity and ventilatory eﬃciency (VO2 peak and VE/
VCO2 slope, respectively): this is a novel observation sug-
gesting that increased sympathetic nerve activation could be
a physiologic adaptive mechanism to hypoxia contributing
to the alveolar wasted hyperventilation typically observed in
patients with PAH, thus leading to further impairment of
exercise capacity and respiratory muscle function.29
We acknowledge that the 123I-MIBG data obtained
derive mainly from the ROI involving mainly the LV.
Nevertheless, taking into account that PAH primarily ori-
ginates as a ‘‘right heart’’ problem, the evidence of adrener-
gic dysfunction involving the ‘‘left side’’ of the heart in those
patients may suggest that the process is ubiquitous.
To our knowledge, this is the ﬁrst study comparing car-
diac sympathetic dysfunction between PAH and HFrEF as
demonstrated by 123I-MIBG imaging. Our results are par-
ticularly relevant since they could represent a rationale for
supporting novel therapeutic approaches for the treatment
of PAH. In particular, it is well known that in patients with
Fig. 3. Correlation between WR and hemodynamic, instrumental, and serum data in PAH patients. NT-proBNP: N-terminal pro brain natriuretic
peptide; PVR: pulmonary vascular resistance; TAPSE: tricuspid annular plane systolic excursion; VCO2: carbon dioxide production per minute; VE:
minute ventilation; VO2: oxygen consumption per kg/min; WR%: washout rate.
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chronic left-sided heart failure, sympathetic hyperactivation
is associated with a higher risk of sudden cardiac death and
ventricular arrhythmias,30 and that this risk is signiﬁcantly
reduced with the use of beta-blockers.31 Likewise, it is plaus-
ible that sympathetic dysfunction could be at least partly
responsible for the higher incidence of sudden cardiac
death in PAH patients.1 The role played by the adrenergic
nervous system in left-sided HFrEF is well established and
the therapeutic eﬀect of beta-blockers represents a corner-
stone of modern treatment. While right ventricular failure is
the main cause of mortality in PAH, there are several dif-
ferences between the LV and RV related to their diﬀerent
shape, embryological origins, structure, circulatory environ-
ments, and pressure overload response.32 In this respect, the
use of beta- and alpha-blockers in PAH is controversial.33
To date, the latest guidelines for treatment of PH discourage
the use of beta-blockers in PAH,1 particularly in portopul-
monary PH, based on results from a small study showing
improved exercise tolerance after beta-blocker withdrawal
in these patients.34 Nevertheless, preclinical studies showed
some beneﬁcial eﬀects in PAH on right ventricle function,
including reversal of RV remodeling, delayed RV failure,35
and improvement of pulmonary vascular remodeling36 in
various models of PH. Recently, some small nonrandomized
clinical studies aimed at evaluating the eﬀects of beta-
blockers in PAH suggest a possible beneﬁcial eﬀect of
beta-blockers as well as their good tolerability.37,38 The
use of beta-blockers is a common practice in PH due to
left-sided HFrEF and in PAH with cardiovascular comor-
bidities with up to 10–30% of these patients receiving one of
this class of drugs.37,38 Two recent randomized placebo-
controlled studies using bisoprolol39 or carvedilol40 in
small cohorts of PAH patients demonstrated good tolerabil-
ity and safety, but no clear clinical beneﬁt or better exercise
capacity, suggesting a lack of clear eﬃcacy in this setting.41
Pharmacological modulation of the adrenergic system in
selected patients with selected agents could be useful in
PAH. Potential beneﬁcial eﬀects may include reverse RV
remodeling and delayed development of RV failure.
However, negative inotropic and chronotropic eﬀects may
limit their clinical use.42,43 Further randomized trials are
needed to better understand which strategy of adrenergic
blockade might be eﬀective in managing sympathetic hyper-
activation in PAH.
Study limitations
There are some limitations to this study. First, as mentioned
in the ‘‘Discussion’’ section, the MIBG data presented
derived mainly from the ROI involving the LV because of
technical issues in visualization and identiﬁcation of speciﬁc
ROI for the right ventricular free wall. However, the ROI
considered included also the interventricular septum, a por-
tion ‘‘shared’’ between the two ventricles that is known to
play a major role in the maintenance of right ventricular
function,44 which when impaired is associated with poor
prognosis in the setting of PH. Another limitation concerns
the relatively small number of enrolled patients, which is
related to the rare prevalence of PAH. Nevertheless, this
limited number of patients does not particularly diﬀer
from other studies on PAH and SNS alterations,11–15 or
on other studies on 123I-MIBG alterations in other noncom-
mon diseases, such as hypertrophic cardiomyopathy,
Anderson–Fabry disease, or Tako-Tsubo syndromes,
which applied ‘‘not widely available’’ techniques for
research purposes.28 Despite the growing evidence of the
important role of cardiac 123I-MIBG as a tool to evaluate
organ-speciﬁc sympathetic nervous dysfunction, its clinical
use has remained very limited because of economic concerns
relative to reimbursement and funding. Even if larger multi-
center randomized trials on cardiac 123I-MIBG use in the
context of HF are emerging, current guidelines encourage
the collection of small data in other ﬁelds not widely
explored yet.28 We did not enroll more patients since this
was an exploratory study.
Conclusions
Our results indicate that patients with PAH have cardiac
sympathetic nervous dysfunction demonstrated with
123I-MIBG imaging that is similar to the impairment
observed in patients with HFrEF. Furthermore, these alter-
ations were strongly correlated with well-recognized prognos-
tic indices. 123I-MIBG cardiac imaging could provide relevant
information for better understanding of the pathophysiology
of PAH. Additional larger studies with adequate follow-up
periods are needed to better interpret the correlations with
hemodynamic and functional parameters and to assess the
prognostic relevance of this imaging technique. The triggers
that induce these alterations in PAH and the role of SNS on
the development of right ventricular dysfunction45 in PAH
with diﬀerent etiologies (e.g. idiopathic versus connective
tissue disease) need to be further investigated. The possible
eﬀect of therapeutic interventions targeting sympathetic acti-
vation in PAH patients remains to be clariﬁed.
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